Polish legislation does not generally allow the growing of cannabis that contains more than 0.2% THC in flowering or fruiting tops of plants from which the resin has not been removed (Non-Fibrous Cannabis). Only by way of exception, scientific entities may grow Non-Fibrous Cannabis after obtaining a permit from the Chief Pharmaceutical Inspector. It is, however, possible to import and sell such cannabis for medical use as a pharmaceutical raw material intended for preparing prescription drugs.
Non-Fibrous Cannabis herb, tinctures, resin and other extracts may constitute a pharmaceutical raw material after obtaining a marketing authorisation issued by the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (granted for a period of five years). The provisions of pharmaceutical law regarding manufacturing and import of medical raw materials and permits required in connection with such materials apply accordingly.
Non-Fibrous Cannabis for medical use is distributed to patients by pharmacies as a prescription medicine, i.e. a medicinal product prepared in a pharmacy on the basis of a medical prescription issued by a doctor.
Violations of the laws concerning Non-Fibrous Cannabis are treated as criminal offences and are punishable by fines or imprisonment.